Publications by authors named "M Blaurock"
Background: Systemic therapy of head and neck squamous cell carcinoma (HNSCC), in contrast to local therapy, is a very general term for the use of drugs that affect the entire organism. Immunotherapy is a subtype of systemic therapy, although the boundaries are hard to define, since the immune system is likely to play an essential role in all treatments. This article focuses on systemic therapy.
View Article and Find Full Text PDFIntroduction: Patients with head and neck cancer (PwHNC) benefit from targeted exercise interventions: symptom relief, compensation for dysfunction, improvement in quality of life (QoL). Data on acceptance physical interventions in PwHNC are rare. The 'OSHO #94' trial investigates the short- and medium-term effects of individualized home exercise in PwHNC on QoL, physical activity and functionality.
View Article and Find Full Text PDF: Obstructive sleep apnea (OSA) is common not only in the general population but even more so in patients with tumors of the head and neck region. Untreated, it leads to reduced quality of life, increased daytime sleepiness, and other comorbidities. The aim of this study was to determine the difference in the occurrence of OSA in the patient population with head and neck tumors compared with the general population as represented by the Trend cohort of the Study of Health in Pomerania (SHIP), and to assess the influence of tumor treatment.
View Article and Find Full Text PDFTolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.
Front Oncol
February 2024
Article Synopsis
- Head and neck squamous cell carcinoma (HNSCC) is a common cancer, and over 50% of patients experience recurrent or metastatic disease despite aggressive treatments, highlighting the need for better therapies.
- The FOCUS trial seeks to compare the effectiveness of the UV1 cancer vaccine combined with pembrolizumab to pembrolizumab alone in treating patients with recurrent or metastatic HNSCC and PD-L1 expression.
- The study adheres to ethical guidelines, aiming to publish findings in scientific journals and at conferences, as it explores new treatment strategies for patients who cannot tolerate traditional chemotherapy.
Background: Liquid biopsy is a promising new diagnostic tool that is already used in clinical practice for multiple tumor entities and which also has great potential for head and neck cancer. Herein, the authors discuss a selection of publications from the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) meetings in 2022.
Objective: Relevant publications are evaluated and summarized.